European Society of Cardiology (ESC) Congress

New Inclisiran Analysis Evaluated LDL-C Reduction Across Individual Patient

Analysis, Atherosclerotic Cardiovascular Disease (ASCVD), Clinical Trials, Data, Elevated Low-Density Lipoprotein Cholesterol (LDL-C), European Medicines Agency (EMA), European Society of Cardiology (ESC) Congress, FDA, Hyperlipidemia, Placebo, Post-Hoc Analysis, Primary Hyperlipidemia, R&D, Small-Interfering RNA (siRNA) Class

Novartis announced results from a post-hoc analysis of pooled data from the Phase III ORION-10 and -11 trials evaluating the individual responses of patients on low-density lipoprotein cholesterol (LDL-C) reduction with inclisiran, a first-in-class investigational treatment for hyperlipidemia in adults.

August 30, 2020/by Andrew Humphreys

Esperion’s Bemopedoic Acid Treatments Hit the Mark in Two Studies

"Bad" LDL Cholesterol, Atherosclerotic Cardiovascular Disease (ASCVD), Clinical Data, Clinical Studies, Clinical Trials, European Society of Cardiology (ESC) Congress, FDA, Marketing Authorization Applications, New Drug Applications, R&D, Statins

Ann Arbor, Mich.-based Esperion Therapeutics reported final results from a long-term safety study of bempedoic acid 180 mg versus placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) whose disease is inadequately controlled by statins.

August 27, 2018/by BioSpace